All
FDA Approves Nerlynx for HER2-Positive Breast Cancer Treatment
July 18th 2017Nerlynx (neratinib) was granted approval by the Food and Drug Administration (FDA) for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer who have already received postoperative Herceptin (trastuzumab).
Blincyto Granted FDA Approval for Leukemia Subset
July 12th 2017Blincyto (blinatumomab) was granted full approval by the Food and Drug Administration (FDA) to treat both children and adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), regardless of Philadelphia chromosome (Ph) status, according to the developer of the anti-CD19 immunotherapy, Amgen.
Abemaciclib Gets a Priority Review to Treat Breast Cancer Subset
July 12th 2017Abemaciclib was granted a priority review to a new drug application (NDA) to treat patients with advanced hormone receptor (HR)­­–positive, HER2-negative breast cancer, according to Eli Lilly and Company, the manufacturer of the CDK4/6 inhibitor.